Multiple-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2009-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A comparison of three products for oral nicotine replacement with respect to pharmacokinetics after multiple-doses of nicotine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Single-dose Nicotine Pharmacokinetics With a New Oral Nicotine Replacement Product

NCT01084603

Tobacco Dependence

COMPLETED NA

Single-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products. A Study in Healthy Smokers.

NCT01234792

Tobacco Dependence

COMPLETED NA

Nicotine Pharmacodynamics With a New Oral Nicotine Replacement Therapy and Nicotine Gum

NCT01368016

Tobacco Dependence

COMPLETED NA

Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products

NCT01234896

Tobacco Dependence

COMPLETED NA

Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum

NCT01152723

Tobacco Dependence

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study compares a new oral Nicotine Replacement Therapy (NRT) product with NiQuitin™ lozenge 4 mg and Nicorette®gum 4 mg, after 12 hours of nicotine abstinence, with respect to steady-state nicotine pharmacokinetics, during 12 hours after start of the first administration. Multiple doses of each treatment are given once hourly during five separate treatment visits scheduled in a crossover setting with randomized treatment sequences. The study will include 40 healthy smokers between 18-50 years, who have been smoking at least 20 cigarettes daily during at least one year preceding inclusion. Subjects and study personnel will be aware of which treatment is administered at a given visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tobacco Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral Nicotine 24-SA

2 Self-administrations of Experimental Nicotine once every hour

Group Type EXPERIMENTAL

Oral Nicotine

Intervention Type DRUG

Oral Nicotine either self-administered or provided by study personnel within 12 hours

Oral Nicotine 24

2 administrations of Experimental Nicotine by study personnel once every hour

Group Type EXPERIMENTAL

Oral Nicotine

Intervention Type DRUG

Oral Nicotine either self-administered or provided by study personnel within 12 hours

Oral Nicotine 48

2 administrations of Experimental Nicotine by study personnel once every 30 minutes

Group Type EXPERIMENTAL

Oral Nicotine

Intervention Type DRUG

Oral Nicotine either self-administered or provided by study personnel within 12 hours

NiQuitin™ Lozenge 4 mg

1 NiQuitin™ lozenge, administered by study personnel once every hour

Group Type ACTIVE_COMPARATOR

Nicotine Lozenge

Intervention Type DRUG

Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours

Nicorette® Gum 4 mg

1 piece Nicorette® gum, chewed for 30 minutes once every hour

Group Type ACTIVE_COMPARATOR

Nicotine gum

Intervention Type DRUG

Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Nicotine

Oral Nicotine either self-administered or provided by study personnel within 12 hours

Intervention Type DRUG

Nicotine Lozenge

Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours

Intervention Type DRUG

Nicotine gum

Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

generic Nicotine NiQuitin™ Nicorette®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy smokers, smoking at least 20 cigarettes daily during at least one year preceding inclusion and BMI between 17.5 and 30.0 kg/m2.
* Female participants of child-bearing potential are required to use a medically acceptable means of birth control.
* A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion Criteria

* Pregnancy, lactation or intended pregnancy.
* Treatment with an investigational product or donation or loss of blood within 3 month preceding the first dose of study medication.
* Prior regular use of nicotine mouth spray

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No